CheckMate 358: Phase I/II Evaluation of Nivolumab Monotherapy in Virus-Associated, Recurrent/Metastatic Gynecologic Cancers

June 2-6, 2017; Chicago, Illinois
Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.
Format: Microsoft PowerPoint (.ppt)
File Size: 485 KB
Released: June 4, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Downloadable slideset on the latest clinical data on the management of endometrial cancer, from Clinical Care Options (CCO)

person default Linda R. Duska, MD, MPH Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue